Article ID Journal Published Year Pages File Type
9005811 Clinical Therapeutics 2005 9 Pages PDF
Abstract
Addition of valsartan therapy to usual care in this model analysis resulted in net cost savings among hypothetical heart-failure patients not receiving ACE inhibitors. Substantial cost savings were realized, regardless of variation in model parameters.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis
Authors
, , , ,